FindTrial
Sign In

The incidence rate of Rifampin-resisitant Staphylococci after short term administration of rifaximin in cirrhotic patients

Incidence of rifampin-resisitant Staphylococci after treating by rifaximin in patients of hepatic encephalopathy or spontaneous bacterial peritonitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0001753
Enrollment
180
Registered
2016-01-05
Start date
2015-03-20
Completion date
Unknown
Last updated
2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Ewha Womans University Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Liver cirrhosis patient who taken rifaximin more than 7 days to prevent hepatic encephalopathy or to manage enterocolitis

Exclusion criteria

Exclusion criteria: 1) who died or was follow up loss 2) who treated with rifampin 3) who administered rifaximin already 4) who judged that cannot be enrolled by researcher

Design outcomes

Primary

MeasureTime frame
Prevalence of rifampin resistant staphylococcus—

Secondary

MeasureTime frame
Rifampin-resistant Staphylococci carrier rate before administer rifaximin—

Countries

Korea, Republic of

Contacts

Public ContactMin Sun Ryu

Ewha Womans University Medical Center

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026